News

Parents advocate for children with chronic skin conditions, highlighting school challenges and the need for better support in pediatric dermatology.

This review of the latest dermatologic studies includes a review of photoprotection in patients with skin of color, the presence of inflammatory cytokines in acne patients after isotretinoin treatment, perceptions of skin-lightening products in medical students, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Shanna Miranti, MPAS, PA-C, discusses the impact of sleep loss in pediatric atopic dermatitis and the potential of emerging therapies in young patients, such as ruxolitinib cream, to improve outcomes.

Unlock exclusive insights from Elevate-Derm Summer 2025 and get expert pearls, emerging data, and clinical strategies at your fingertips.

Virginia Sybert, MD, emphasized the importance of using genetic testing judiciously in dermatologic care.

According to a new poster, patients with chronic spontaneous urticaria seek better relief options, highlighting significant impacts on quality of life and mental well-being globally.

Immutep advances eftilagimod alfa for head and neck squamous cell carcinoma, targeting patients with low PD-L1 expression and limited treatment options.

Temitayo Ogunleye, MD, guided clinicians through diverse AD cases to examine how newer agents fit into evolving treatment strategies.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

New clinical trial results reveal that intratumoral vidutolimod combined with pembrolizumab shows promise for treating advanced melanoma resistant to PD-1 therapy.

Cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitors (ICIs) show distinct immune profiles from classic skin conditions.

Dendy Engelman, MD, FACMS, FAAD, explores the benefits of EVERESSE monopolar RF technology, emphasizing safety, comfort, and effective skin rejuvenation.

Amlitelimab shows promise in enhancing clinical outcomes and patient quality of life in atopic dermatitis, offering potential for long-term disease control.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about Johnson & Johnson's sBLA for guselkumab structural damage data, insights from LEO Pharma on the recent delgocitinib approval, the FDA's Fast Track designation for rezpegaldesleukin, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dendy Engelman, MD, FACMS, FAAD, explores the latest advancements in laser and energy-based dermatological treatments, including skin resurfacing and body contouring.

Kolansky identifies oxybenzone and fragrances as leading causes of sunscreen allergies.

Whitney Hovenic, MD's new SPOOGE sunscreen hopes to engage Gen Z in sun protection, merging skincare with fun and effective sun care strategies.

The Japanese study found no association between cutaneous events and baseline EASI scores, eosinophil counts, or IgE levels.

Michael Somenek, MD, shares how a first-of-its-kind Galderma trial using Sculptra and Restylane helped restore volume and skin quality in patients on GLP-1 medications.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of August.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Deucravacitinib-treated patients achieved superior clinical responses compared to placebo at week 16 in both trials.

In a discussion on pediatric AD management, Shanna Miranti, MPAS, PA-C, emphasized the enduring role of topical treatments for residual itch and flares, and highlighted the importance of rapid-acting agents such as ruxolitinib cream.

Discover how the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai leads in innovative skin cancer care and research, celebrating a decade of excellence.

Renata Block, DMSc, MMS, PA-C, interviews Adam Friedman, MD, FAAD, about his research into cannabidiol’s photoprotective potential, clinical trial design, and future directions.